Vynotec Unveils 'Nano Delivery Technology' in Europe... K-Beauty Tech Competition Heats Up View original image

Vynotec Co., Ltd. (CEO Kim Yumi) announced that it participated in Cosmoprof Worldwide Bologna, the world’s largest beauty industry trade show, held in Bologna, Italy from March 26, where it unveiled products and ingredients utilizing its nano drug delivery technology.


At this exhibition, Vynotec showcased its high-content, function-focused products, highlighting technical features that enhance the absorption rate and delivery efficiency of active ingredients.


A Vynotec representative stated, “On-site, the key evaluation criterion was not simply increasing ingredient content, but rather how effectively the ingredient is delivered to the skin or inside the body,” adding, “We confirmed a trend shifting beyond just functionality, now also emphasizing delivery efficiency and technological competitiveness.”


Vynotec exhibited products based on its nano drug delivery technology (Drug Delivery System), as well as patented materials and fermented ingredients.


The cosmetics brand REPOVE was introduced as featuring Hydroethosome and Hydropatisome technologies to improve the skin delivery efficiency of active ingredients, while the functional food supplement ABSOVE was described as combining fermentation-based low-molecular conversion technology with a delivery system.


Vynotec has completed registration of a related U.S. patent for its nano drug delivery technology and has also received a patent registration decision from the European Patent Office (EPO) for its next-generation delivery platform, the Absosome® technology.


Europe is known for its strict patent review standards. Regarding this, a Vynotec representative explained, “Participating in a local exhibition after receiving the patent registration decision from the European Patent Office is significant in terms of technological competitiveness and validation.”


The Vynotec representative added, “At this exhibition, we observed that the global beauty industry is shifting from ingredient-centric competition to simultaneously considering delivery technology and efficiency. During the event, we held consultations with buyers from Europe, the Middle East, Southeast Asia, and the Americas on distribution and collaboration, discussing various forms of cooperation including ingredient supply, OEM/ODM, and finished product distribution.”



They further stated, “By May, we plan to complete the establishment of a GMP production infrastructure capable of manufacturing everything from nano drug delivery ingredients to finished products. Through this, we aim to promote localization of ingredients, quality control, and supply stability.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing